<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02933801</url>
  </required_header>
  <id_info>
    <org_study_id>SAKK 08/16</org_study_id>
    <nct_id>NCT02933801</nct_id>
  </id_info>
  <brief_title>ODM-201 Maintenance Therapy in Patients With mCRPC Previously Treated With Novel Hormonal Agents.</brief_title>
  <official_title>ODM-201 Maintenance Therapy in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) Previously Treated With Novel Hormonal Agents and Non-progressive Disease After Subsequent Treatment With a Taxane: A Multicenter Randomized Double-blind Placebo-controlled Phase II Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Swiss Group for Clinical Cancer Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Swiss Group for Clinical Cancer Research</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of the trial is to assess impact of maintenance therapy with ODM-201 on
      radiographic progression-free survival (rPFS) of patients with mCRPC pretreated with novel
      hormonal agents who have non-progressive disease after chemotherapy with a taxane.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The treatment of metastatic castration-resistant prostate cancer has evolved rapidly over the
      past few years. First line treatment with one of the novel antihormonal drugs abiraterone or
      enzalutamide followed by chemotherapy with docetaxel is now standard of care. If a patient
      has disease stabilization on chemotherapy he undergoes a watchful waiting period and further
      treatment is only started at the time of disease progression. This trial tests the immediate
      use of the novel androgen receptor antagonist ODM-201 as maintenance treatment after
      chemotherapy aiming at prolonging radiographic progression free survival as compared to
      watchful waiting.

      The main objective of the trial is to assess impact of maintenance therapy with ODM-201 on
      radiographic progression-free survival (rPFS) of patients with mCRPC pretreated with novel
      hormonal agents who have non-progressive disease after chemotherapy with a taxane.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 31, 2017</start_date>
  <completion_date type="Anticipated">December 2026</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Radiographic progression-free survival (rPFS) at 12 weeks</measure>
    <time_frame>At 12 weeks after treatment start</time_frame>
    <description>Radiographic progression-free survival is defined as the time from treatment start to radiographic disease progression or death from any cause, whichever occurs earlier.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Radiographic progression-free survival (rPFS)</measure>
    <time_frame>Every 12 weeks until disease progression (estimated up to 1 year)</time_frame>
    <description>Radiographic progression-free survival is defined as the time from treatment start to radiographic disease progression or death from any cause, whichever occurs earlier.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to PSA progression</measure>
    <time_frame>PSA level at baseline and every 4 weeks until disease progression (estimated up to 1 year)</time_frame>
    <description>PSA progression is defined as:
In case PSA levels had not decreased under treatment with the study drug: ≥ 25% increase over baseline (last PSA measurement before treatment start) AND an increase in the absolute PSA value of ≥ 5 ng/mL.
In case of PSA response &lt; 50% under treatment with the study drug: ≥ 25% increase over the nadir AND an increase in the absolute PSA value of ≥ 5 ng/mL.
In case of PSA response ≥ 50% under treatment with the study drug: ≥ 50% increase over the nadir AND an increase in the absolute PSA value of ≥ 5 ng/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to symptomatic/clinical progression</measure>
    <time_frame>treatment start to the time point of symptomatic/clinical progression (estimated up to 1 year)</time_frame>
    <description>Symptomatic/clinical progression is defined by one of the following:
Occurrence of a SRE due to bone metastases, defined as pathologic fracture, spinal cord compression, palliative radiation to bone, or surgery to bone
Treating physician decides for intervention due to new disease related complications (e.g., urinary obstruction, hydronephrosis)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event-free survival</measure>
    <time_frame>treatment start until the event of interest (estimated up to 1 year)</time_frame>
    <description>Event-free survival is defined as the time from treatment start until the event of interest.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>time from trial randomization to the date of death from any cause (estimated up to 6 years)</time_frame>
    <description>Overall survival is defined as the time from treatment start until death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PSA response (30%, 50%, 90% and best)</measure>
    <time_frame>PSA level at baseline and every 4 weeks until disease progression (estimated up to 1 year)</time_frame>
    <description>30% PSA response is defined as a decrease in PSA level of at least 30% (compared to baseline PSA).
50% PSA response is defined as a decrease in PSA level of at least 50% (compared to baseline PSA).
90% PSA response is defined as a decrease in PSA level of at least 90% (compared to baseline PSA).
Best PSA response is defined as the percentage of change in PSA from baseline to the maximum decline in PSA at any point under treatment. If there is a steady increase after baseline, the best response is defined as the percentage of change in PSA from baseline to the minimum increase in PSA at any point under treatment. Baseline is defined as the latest recorded measurement prior to the first dose of trial treatment.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">88</enrollment>
  <condition>Prostate Cancer Metastatic</condition>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Arm A: ODM-201</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>600mg ODM-201 BID (twice daily) and Best Supportive Care until progression</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo BID (twice daily) and Best Supportive Care until progression</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ODM-201</intervention_name>
    <description>ODM-201 will be given at a dose of 600 mg BID orally on a continuous basis.</description>
    <arm_group_label>Arm A: ODM-201</arm_group_label>
    <other_name>BAY-1841788</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo will be given at a dose of 600 mg BID orally on a continuous basis.</description>
    <arm_group_label>Arm B: Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent according to Swiss law and ICH/GCP regulations before
             registration and prior to any trial specific procedures not part of normal medical
             care.

          -  Histologically or cytologically confirmed diagnosis of adenocarcinoma of the prostate

          -  Castration resistance: tumor progression after orchiectomy or during treatment with
             GnRH analogues (agonists or antagonists)

          -  Metastatic disease, documented by imaging

          -  Total testosterone ≤ 50 ng/dL (≤ 1.7 nmol/L)

          -  Treatment with abiraterone AND/OR enzalutamide for at least 8 weeks prior to taxane
             based chemotherapy

          -  No evidence of disease progression after chemotherapy with docetaxel (at least
             cumulative dose of ≥ 300 mg/m2 or total dose ≥ 600mg) or cabazitaxel (at least
             cumulative dose of ≥ 80 mg/m2 or total dose ≥ 160 mg)

               -  No evidence of progression on imaging according to PCWG3

               -  No evidence of progression on PSA levels referred to the nadir since start of
                  taxane treatment (PSA progression defined as &gt; 25% increase of PSA level or &gt;50%
                  if PSA decrease under chemotherapy &gt;50% AND &gt; 5 ng/mL increase in the absolute
                  PSA value)

          -  Non-surgically castrated patient agrees on ongoing use of GnRH analogues (agonists or
             antagonists) during the trial

          -  Planned start of trial treatment 2 to 8 weeks after last taxane dose

          -  Male patient 18 years or older

          -  WHO performance status of ≤2

          -  Laboratory values as specified below

               -  alanine aminotransferase (ALT) ≤ 2.5 x ULN (except for patients with liver
                  metastases ≤ 5.0 x ULN)

               -  Total bilirubin ≤ 1.5 x ULN (except for patients with Gilbert's disease ≤ 3.0 x
                  ULN)

               -  Estimated creatinine clearance using the Cockcroft-Gault formula &gt; 30 mL/minute

               -  Blood counts at screening: haemoglobin ≥ 90 g/L, absolute neutrophil count ≥
                  1500/μl (1.5x109/L), platelet count ≥ 100,000/μl (100x109/L) (patient must not
                  have received any growth factor or blood transfusion within 7 days of the
                  haematology laboratory obtained at screening)

          -  Adequate cardiac function: Left ventricular Ejection Fraction (LVEF) ≥ 40% as
             determined by echocardiography (ECHO)

          -  Patient is able and willing to swallow trial drug as whole tablet

          -  Sexually active male subjects must agree to use condoms as an effective barrier method
             and refrain from sperm donation, and/or their female partners of reproductive
             potential to use a method of effective birth control, during the study treatment and
             for 3 months after the end of the treatment.

          -  Patient agrees to participate in the mandatory translational research project

        Exclusion Criteria:

          -  Prior chemotherapy for prostate cancer except from chemotherapy with a taxane

          -  Concurrent disease requiring higher doses of corticosteroid than the equivalent of 10
             mg prednisone per day

          -  Known CNS or leptomeningeal metastases

          -  Clinical or radiological evidence of current spinal cord compression

          -  History of hematologic or primary solid tumor malignancy, unless in remission for at
             least 2 years from registration with the exception of localized non-melanoma skin
             cancer or carcinoma in situ having undergone complete resection.

          -  Prior therapy for mCRPC with modern anti-hormonal treatment except for enzalutamide or
             abiraterone

          -  Concurrent treatment with other experimental drugs or treatment in a clinical trial
             within 30 days prior to trial entry (except clinical trial SAKK 96/12)

          -  Concomitant use of other anti-cancer drugs or radiotherapy except for local pain
             control and GnRH analogues

          -  Severe or uncontrolled cardiovascular disease

          -  Acute exacerbations of chronic illnesses, serious infections, or major surgery within
             4 weeks before expected start of treatment

          -  ECG abnormalities of Q-wave infarction, unless identified ≥ 6 months prior to
             registration or QTc interval &gt;480 msec

          -  Known gastrointestinal (GI) disease or GI procedure that could interfere with the GI
             absorption or tolerance of ODM-201

          -  Known hypersensitivity to trial drug or to any component of the trial drug

          -  Any other serious underlying medical, psychiatric, psychological, familial or
             geographical condition, which in the judgment of the investigator may interfere with
             the planned staging, treatment and follow-up, affect patient compliance or place the
             patient at high risk from treatment-related complications.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Silke Gillessen, Prof</last_name>
    <role>Study Chair</role>
    <affiliation>Cantonal Hospital of St. Gallen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eloïse Kremer, PhD</last_name>
    <phone>+41 31 389 91 91</phone>
    <email>trials@sakk.ch</email>
  </overall_contact>
  <location>
    <facility>
      <name>European Institute of Oncology (EIO)</name>
      <address>
        <city>Milano</city>
        <zip>20141</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Franco Nole, MD</last_name>
      <phone>Phone: +39 (0)2 574 89 502</phone>
      <email>franco.nole@ieo.it</email>
    </contact>
    <investigator>
      <last_name>Franco Nole, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale dei Tumori - IRCCS Fondazione</name>
      <address>
        <city>Milano</city>
        <zip>20141</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giuseppe Procopio, MD</last_name>
      <phone>+39 (0)2 239 02 557</phone>
      <email>giuseppe.procopio@istitutotumori.mi.it</email>
    </contact>
    <investigator>
      <last_name>Giuseppe Procopio, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale dei Tumori - IRCCS Fondazione Pascale S.C.</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gaetano Facchini, MD</last_name>
      <phone>+39 (0)2 239 04 450</phone>
      <email>g.facchini@istitutotumori.na.it</email>
    </contact>
    <investigator>
      <last_name>Gaetano Facchini, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AOU &quot;Maggiore della Carità&quot; di S.C. di Oncologia</name>
      <address>
        <city>Novara</city>
        <zip>28100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alessandra Mosca, MD</last_name>
      <phone>+39 (0)3 213 73 2115</phone>
      <email>alessandramosca25@yahoo.it</email>
    </contact>
    <investigator>
      <last_name>Alessandra Mosca, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AOU San Luigi Gonzaga</name>
      <address>
        <city>Orbassano</city>
        <zip>10043</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giorgio Vittorio Scagliotti, Prof</last_name>
      <phone>+39 (0)1 190 26 979</phone>
      <email>giorgio.scagliotti@unito.it</email>
    </contact>
    <investigator>
      <last_name>Giorgio Vittorio Scagliotti, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AO San Camillo and Forlanini Hospitals</name>
      <address>
        <city>Roma</city>
        <zip>00152</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cora N. Sternberg, MD</last_name>
      <phone>+39 (0)6 663 0771</phone>
      <email>cstern@mclink.it</email>
    </contact>
    <investigator>
      <last_name>Cora N. Sternberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Presidio Ospedaliero Santa Chiara</name>
      <address>
        <city>Trento</city>
        <zip>38122</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Orazio Caffo, MD</last_name>
      <phone>+39 (0)4 61 902 121</phone>
      <email>orazio.caffo@apss.tn.it</email>
    </contact>
    <investigator>
      <last_name>Orazio Caffo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Integrate Verona (AOUI)</name>
      <address>
        <city>Verona</city>
        <zip>37126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gianpaolo Tortora, Prof</last_name>
      <email>giampaolo.tortora@univr.it</email>
    </contact>
    <investigator>
      <last_name>Gianpaolo Tortora, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Baden</name>
      <address>
        <city>Baden</city>
        <zip>CH-5404</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas Erdmann, MD</last_name>
      <phone>+41 56 486 27 62</phone>
      <email>andreas.erdmann@ksb.ch</email>
    </contact>
    <investigator>
      <last_name>Andreas Erdmann, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto Oncologico della Svizzera Italiana - Ospedale Regionale Bellinzona e Valli</name>
      <address>
        <city>Bellinzona</city>
        <zip>6500</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Enrico Roggero, MD</last_name>
      <email>roggero@ticino.com</email>
    </contact>
    <investigator>
      <last_name>Enrico Roggero, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Graubuenden</name>
      <address>
        <city>Chur</city>
        <zip>7000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard Cathomas, MD</last_name>
      <phone>+41 81 256 66 95</phone>
      <email>richard.cathomas@ksgr.ch</email>
    </contact>
    <investigator>
      <last_name>Richard Cathomas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Fribourg HFR</name>
      <address>
        <city>Fribourg</city>
        <zip>1708</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marc Küng, MD</last_name>
      <phone>+41 26 426 72 43</phone>
      <email>marc.kueng@h-fr.ch</email>
    </contact>
    <investigator>
      <last_name>Marc Küng, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Liestal</name>
      <address>
        <city>Liestal</city>
        <zip>CH-4410</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bettina Seifert, MD</last_name>
      <phone>+41 61 925 34 03</phone>
      <email>bettina.seifert@ksli.ch</email>
    </contact>
    <investigator>
      <last_name>Bettina Seifert, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fondazione Oncologia / Oncologia ematologia</name>
      <address>
        <city>Locarno</city>
        <zip>6600</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Augusto Pedrazzini, MD</last_name>
      <phone>+41 91 752 3535</phone>
      <email>a.pedrazzini@oncologia-pedrazzini.ch</email>
    </contact>
    <investigator>
      <last_name>Augusto Pedrazzini, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Muensterlingen</name>
      <address>
        <city>Münsterlingen</city>
        <zip>8596</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roman Inauen, MD</last_name>
      <phone>+41 71 686 11 11</phone>
      <email>roman.inauen@stgag.ch</email>
    </contact>
    <investigator>
      <last_name>Roman Inauen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital du Valais (Sion et Martigny)</name>
      <address>
        <city>Sion</city>
        <zip>1951</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandro Anchisi, MD</last_name>
      <phone>+41 27 603 45 00</phone>
      <email>sandro.anchisi@hopitalvs.ch</email>
    </contact>
    <investigator>
      <last_name>Sandro Anchisi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kantonsspital - St. Gallen</name>
      <address>
        <city>St. Gallen</city>
        <zip>CH-9007</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Silke Gillessen, Prof</last_name>
      <phone>+41 71 494 10 92</phone>
      <email>Silke.gillessen@kssg.ch</email>
    </contact>
    <investigator>
      <last_name>Silke Gillessen, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Spital STS AG</name>
      <address>
        <city>Thun</city>
        <zip>CH-3600</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Rauch, MD</last_name>
      <phone>+41 33 226 26 45</phone>
      <email>daniel.rauch@spitalstsag.ch</email>
    </contact>
    <investigator>
      <last_name>Daniel Rauch, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 13, 2016</study_first_submitted>
  <study_first_submitted_qc>October 13, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 14, 2016</study_first_posted>
  <last_update_submitted>April 10, 2018</last_update_submitted>
  <last_update_submitted_qc>April 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>metastatic castration resistant prostate cancer (mCRPC)</keyword>
  <keyword>Prostate Cancer</keyword>
  <keyword>phase II trial</keyword>
  <keyword>ODM-201</keyword>
  <keyword>maintenance therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

